Nano-X Image Guidance: CBCT With Gravity-induced Motion
Launched by UNIVERSITY OF SYDNEY · Jul 23, 2020
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to use imaging technology to help guide radiation therapy for cancer patients. The study focuses on using a special imaging system called cone beam computed tomography (CBCT), which creates detailed pictures of the inside of the body. Instead of moving the imaging equipment, the trial will rotate the patient gently to capture these images. This is an early-stage trial, meaning it's still in the testing phase to see if this method works well and is safe for patients.
To participate in this trial, you need to be a cancer patient aged 60 or older who is receiving radiation therapy for tumors in specific areas like the head, neck, chest, abdomen, or pelvis. You'll also need to be able to communicate clearly in English and provide consent to take part in the study. If you join, you can expect a non-invasive experience where you’ll be guided through the imaging process, and your comfort will be prioritized. It’s important to know that this trial is not yet recruiting participants, so if you're interested, you'll need to wait until they start looking for volunteers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Cancer patients that are receiving radiation therapy that are able to be imaged with the Nano-X PRS with one of the following tumour sites:
- • 1. in the head/neck region
- • 2. in the chest/abdomen/pelvic region with fast CBCT used for standard of care image guidance and is aged 60 years or older
- • 3. in the chest/abdomen/pelvic region not receiving CBCT for standard of care image guidance and is aged 70 years or older
- • 4. diagnosis of lung cancer with stage II-IV
- • 2. ≥18 years of age
- • 3. ECOG Performance Status 0-2
- 4. Must be able to communicate fluently in English to:
- • i. Receive instructions from operators of the PRS for safety entering and leaving the Patient Rotation System and required conduct during the during the rotation session, and ii. Communicate their level of comfort or distress to operators of the equipment.
- • 5. Signed, written informed consent or approved alternative, non-contact method for informed consent.
- Exclusion Criteria:
- • 1. Pregnant women
- • 2. Patients for whom attaining informed consent would not be possible, including mentally impairment
- • 3. Patients with severe vertigo or recent a diagnosis of Benign Paroxysmal Positioning Vertigo.
About University Of Sydney
The University of Sydney is a leading research institution in Australia, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university fosters a collaborative environment that integrates cutting-edge research with clinical practice. The institution emphasizes ethical standards, patient safety, and scientific rigor in its trials, aiming to translate findings into real-world applications that benefit diverse populations. Through its dedication to excellence and impact, the University of Sydney continues to contribute significantly to the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Paul J Keall, PhD
Principal Investigator
ACRF Image X Institute, University of Sydney
Michael Jackson, MD
Principal Investigator
Prince of Wales Hospital
Simon Downes, MASc
Study Chair
Prince of Wales Hospital
Mark Gardner, PhD
Study Chair
ACRF Image X Institute, University of Sydney
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials